Atossa Genetics (ATOS) Stock Price, News & Analysis

Company Overview

Atossa Genetics, Inc., now operating as Atossa Therapeutics, Inc. (NASDAQ: ATOS), is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other diseases affecting breast tissue. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.

Atossa’s principal investigational product is oral endoxifen, a selective estrogen receptor modulator being evaluated in clinical studies involving patients with hormone receptor-positive breast cancer. The company has studied endoxifen in several settings, including the presurgical treatment of breast cancer and approaches intended to reduce the risk of developing or recurring breast cancer. Its development programs remain subject to clinical testing and regulatory review.

Founded in 2009, the company was originally known as Atossa Genetics before adopting the Atossa Therapeutics name to reflect its broader therapeutic development focus. Atossa is headquartered in Seattle, Washington, and its clinical research activities may involve sites and collaborators in multiple regions. Steven Quay, M.D., Ph.D., is the company’s founder and chief executive officer.

Key Stats

• Today's Range: $2.22 to $2.38
• 50-Day Range: $2.07 to $2.79
• 52-Week Range: $1.70 to $19.35
• Volume: 39,577 shs
• Average Volume: 41,865 shs
• Market Capitalization: $22.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.33
• Consensus Rating: Hold

Atossa Genetics Stock Analysis - MarketRank™

Atossa Genetics scored higher than 39% of companies evaluated by MarketBeat, and ranked 639th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Atossa Genetics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

Atossa Genetics has a consensus price target of $20.33, representing about 815.9% upside from its current price of $2.22.

Amount of Analyst Coverage

Atossa Genetics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atossa Genetics are expected to grow in the coming year, from ($3.95) to ($3.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atossa Genetics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atossa Genetics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atossa Genetics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.40% of the float of Atossa Genetics has been sold short.

Short Interest Ratio / Days to Cover

Atossa Genetics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Atossa Genetics has recently decreased by 4.99%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atossa Genetics does not currently pay a dividend.

Dividend Growth

Atossa Genetics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

7 people have searched for ATOS on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

3 people have added Atossa Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Atossa Genetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.80% of the stock of Atossa Genetics is held by insiders.

Percentage Held by Institutions

12.74% of the stock of Atossa Genetics is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ATOS
• CIK: 1488039
• Web: atossatherapeutics.com
• Phone: (206) 588-0256
• Fax: 206-430-1288
• Employees: 14
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Atossa Genetics: $20.33
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +815.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -102.99%
• Return on Assets: -85.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.69
• Quick Ratio: 5.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.57 per share
• Price / Book: 0.49

Miscellaneous

• Outstanding Shares: 9,980,000
• Free Float: 9,001,000
• Market Cap: $22.16 million
• Optionable: Optionable
• Beta: 1.27